Bicocca Open Archive

Logo unimib boa
BIAGI, ETTORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.522
AS - Asia 5.449
EU - Europa 4.563
SA - Sud America 752
AF - Africa 130
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 11
Totale 24.442
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.804
SG - Singapore 1.954
CN - Cina 1.267
HK - Hong Kong 738
SE - Svezia 717
RU - Federazione Russa 688
VN - Vietnam 669
CA - Canada 639
DE - Germania 619
BR - Brasile 578
IT - Italia 546
UA - Ucraina 494
IE - Irlanda 464
GB - Regno Unito 295
FR - Francia 207
IN - India 183
FI - Finlandia 143
BD - Bangladesh 101
TR - Turchia 87
KR - Corea 78
AR - Argentina 71
NL - Olanda 71
IQ - Iraq 57
AT - Austria 53
ID - Indonesia 52
MX - Messico 52
ES - Italia 50
BE - Belgio 46
PL - Polonia 46
PK - Pakistan 39
ZA - Sudafrica 39
DK - Danimarca 38
JP - Giappone 38
SA - Arabia Saudita 29
PH - Filippine 28
EC - Ecuador 23
BG - Bulgaria 22
VE - Venezuela 19
CO - Colombia 17
CL - Cile 16
UZ - Uzbekistan 16
TN - Tunisia 14
EG - Egitto 12
ET - Etiopia 11
IL - Israele 11
IR - Iran 11
RO - Romania 11
EU - Europa 10
MA - Marocco 10
MY - Malesia 10
NP - Nepal 10
BO - Bolivia 8
JM - Giamaica 8
JO - Giordania 8
KE - Kenya 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
CH - Svizzera 7
KZ - Kazakistan 7
AL - Albania 6
AZ - Azerbaigian 6
DZ - Algeria 6
NG - Nigeria 6
TH - Thailandia 6
BY - Bielorussia 5
CZ - Repubblica Ceca 5
MU - Mauritius 5
OM - Oman 5
PY - Paraguay 5
RS - Serbia 5
TW - Taiwan 5
AO - Angola 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
SN - Senegal 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
KW - Kuwait 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
PE - Perù 3
PR - Porto Rico 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BH - Bahrain 2
GA - Gabon 2
LB - Libano 2
LK - Sri Lanka 2
NO - Norvegia 2
PS - Palestinian Territory 2
RW - Ruanda 2
SI - Slovenia 2
Totale 24.415
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.605
Ashburn 1.251
Woodbridge 1.238
Singapore 1.096
Fairfield 876
Houston 822
Hong Kong 725
Chandler 717
Wilmington 693
Jacksonville 518
San Jose 459
Toronto 457
Dublin 455
Seattle 383
Frankfurt am Main 350
Cambridge 335
Dearborn 316
New York 240
Beijing 218
Princeton 194
Ho Chi Minh City 190
Santa Clara 180
Los Angeles 171
Chicago 156
Nanjing 135
Hanoi 133
Milan 130
Hefei 127
The Dalles 113
Shanghai 91
Dallas 88
Lawrence 85
Lachine 83
Lauterbourg 81
Council Bluffs 72
Altamura 68
Seoul 68
Buffalo 63
Boardman 60
Dong Ket 60
Moscow 60
São Paulo 56
Vienna 49
San Diego 48
Helsinki 45
Brussels 44
Orem 42
Nanchang 38
Warsaw 37
Montreal 35
Tianjin 35
London 34
Andover 33
Guangzhou 33
Lissone 33
Da Nang 31
Shenyang 31
Fremont 30
Hebei 27
Mountain View 26
Rio de Janeiro 26
Stockholm 26
Denver 25
Hangzhou 25
Munich 25
Baghdad 24
Huizen 23
Amsterdam 22
Atlanta 22
Rome 22
Tokyo 22
Brooklyn 21
Changsha 21
Zhengzhou 21
Chennai 20
Plovdiv 20
Jakarta 18
Jinan 18
Ningbo 18
Poplar 18
Salt Lake City 18
Manchester 17
Ottawa 17
Haiphong 16
Jiaxing 16
Mexico City 16
San Francisco 16
Boston 15
Falls Church 14
Johannesburg 14
Kocaeli 14
Nürnberg 14
Philadelphia 14
Tashkent 14
Auburn Hills 13
Biên Hòa 13
Dhaka 13
Jeddah 13
Phoenix 13
University Park 13
Totale 16.599
Salva come PNG Salva come JPEG
Nome #
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 485
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 467
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 440
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 433
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 425
Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories 417
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 408
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy 393
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 385
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring 383
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 381
Interleukin-17-producing t-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation 365
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 354
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 352
Immunotherapy of acute leukemia by chimeric antigen receptormodified lymphocytes using an improved Sleeping Beauty transposon platform 349
T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy 344
Stable Expression Of Chimeric Antigen Receptors (CARs) By Sleeping Beauty-Mediated Gene Transfer and Efficient Expansion Of Leukemia-Specific Cytokine-Induced Killer (CIK) Cells 341
Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. 338
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 333
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population 328
Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation 311
Characterization of Plated Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects 310
Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells 309
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy 308
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia 303
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 293
Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target primary Acute Myeloid Leukemia cells in vivo 292
Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors 289
Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives 288
Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies 288
Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain 284
Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. 282
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease 282
Donor-derived CD19-targeted T cells in allogeneic transplants 279
Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library 277
GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy 277
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor 271
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 270
A life-threatening paediatric case of acute autoimmune haemolytic anaemia (AIHA) successfully cured by plasma-exchange and combined immunosuppressive treatment 266
Cytokine Induced Killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors 265
Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor 264
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells 260
Long-term effects of bone marrow transplantation on dental status in children with leukaemia 259
Targeting of Acute Myeloid Leukemia by Cytokine-Induced Killer Cells Redirected with a Novel CD123-Specific Chimeric Antigen Receptor 259
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 258
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 257
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes 255
Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis 255
Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device 254
Development of an alveolar bone regeneration protocol with mesenchyl stem cells for the therapy of severe bone resorption in periodontal disease 252
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission 252
Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with crohn's disease 250
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine 247
Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches 247
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells 246
Antigen-induced regulatory T cells 242
CD40 activation of BCP-ALL cells generates 11L-10-producing, 11L-12-defective APCs that induce allogeneic T-cell anergy 240
Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience 240
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs 237
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia 232
Estudio experimental sobre la utilización de células madre humanas en la terapia de los defectos periodontales: resultados preliminares 226
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes 225
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. 224
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells 223
Role of early diagnosis for a noninvasive treatment of pulmonary thromboembolism in leukemic children 220
Chimeric Antigen Receptor for Specific Targeting of Acute Myeloid Leukemia 219
PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. 218
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia 218
Intrathecal chemotherapy with antineoplastic agents in children 214
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells 210
Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells 208
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis 207
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 203
Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies 201
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: A case report 199
A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization 197
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia 194
CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia 193
New findings about the Interplay among Clarithromycin, Immune and Central Nervous Systems 188
From Bone Marrow Transplantation to Cellular Therapies: Possible therapeutic strategies in managing autoimmune disorders 184
In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy 182
Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside 180
New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future 179
Effectiveness of extracorporeal photochemotherapy in treating long-term refractory chronic graft-versus-host disease 179
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma 177
LONG TERM SURVIVAL AND EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT DEPENDENT ON IMMUNOSUPPRESSIVE TREATMENT. 171
Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells 165
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 161
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin 161
Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy 158
Long term efficacy of human bone marrow mesenchymal stem cells in traumatized mice brain is not affected by immunosuppressive treatment 153
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 137
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 126
Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo 83
Totale 24.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021195 0 0 0 0 0 0 0 0 0 0 0 195
2021/20221.376 51 135 208 106 71 68 58 66 138 134 98 243
2022/20232.350 271 730 195 222 136 353 24 149 170 6 68 26
2023/20241.345 44 38 61 55 198 347 263 62 110 8 30 129
2024/20252.935 182 328 134 139 252 74 137 116 377 471 236 489
2025/20267.508 780 466 503 844 999 445 960 392 707 686 580 146
Totale 24.854